Role of fulvestrant in the management of postmenopausal breast cancer.
about
TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.Fulvestrant for the treatment of endometrial cancer.miRNA clusters as therapeutic targets for hormone-resistant breast cancer.Enhancement of the bioavailability of a novel anticancer compound (acetyltanshinone IIA) by encapsulation within mPEG-PLGA nanoparticles: a study of formulation optimization, toxicity, and pharmacokinetics
P2860
Role of fulvestrant in the management of postmenopausal breast cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Role of fulvestrant in the management of postmenopausal breast cancer.
@en
Role of fulvestrant in the management of postmenopausal breast cancer.
@nl
type
label
Role of fulvestrant in the management of postmenopausal breast cancer.
@en
Role of fulvestrant in the management of postmenopausal breast cancer.
@nl
prefLabel
Role of fulvestrant in the management of postmenopausal breast cancer.
@en
Role of fulvestrant in the management of postmenopausal breast cancer.
@nl
P2093
P2860
P356
P1476
Role of fulvestrant in the management of postmenopausal breast cancer.
@en
P2093
Adam Januszewski
Carlo Palmieri
Jonathan Krell
Kelvin Yan
P2860
P304
P356
10.1586/ERA.11.138
P577
2011-11-01T00:00:00Z